

**FAX**

To Office of Initial Patent Examination's  
Filing Receipt Correction

Company USPTO

Fax 703-746-9195

From Marjorie J. Pfeiffer

Tel 1-919-483-9038; Facsimile: 1-919-483-7988

E-mail [marjorie.j.pfeiffer@gsk.com](mailto:marjorie.j.pfeiffer@gsk.com)

Date July 19, 2004 Pages including cover 4

Subject Request for Corrected Filing Receipt

GlaxoSmithKline  
PO Box 13398  
Five Moore Drive  
Research Triangle Park  
North Carolina 27709

Tel: 919 483 2100  
[www.gsk.com](http://www.gsk.com)

Re: Application of Curt Dale HAFFNER et al.  
U.S. Serial No.: 10/637,190; Filed: August 8, 2003  
Title: *Use of FXR Ligands*  
Attorney Docket No. PU3616US2

**Attached:**

1. Request for Corrected Filing Receipt with a Certificate of Transmission (37 CFR 1.8(a))
2. Copy of Filing Receipt

The information contained in these documents is confidential and may also be privileged and is intended for the exclusive use of the addressee designated above. If you are not the intended recipient or the employee or agent responsible to deliver it to the intended recipient, any disclosure, reproduction, distribution, or any other dissemination or use of this communication is strictly prohibited. If you have received this transmission in error please contact us immediately by telephone so that we can arrange for its return.

Atty. Dkt. No. PU3616US2

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Curt Dale HAFFNER et al.

Serial No.: 10/637,190

Filed: 8 August 2003

For: *Use of FXR Ligands*

Unit: 1626

Examiner: Anderson, Rebecca L.

Commissioner for Parents  
 P.O. Box 1450  
 Alexandria, VA 22313-1450

## REQUEST FOR CORRECTED FILING RECEIPT

1. Attached is a copy of the official filing receipt received from the PTO in the above application for which issuance of a corrected filing receipt is respectfully requested.
2. There is an error with respect to the following data, which is:

 incorrectly entered


and/or

 omitted.

- Error in
1.  Applicant's name
  2.  Applicant's address
  3.  Title
  4.  Filing date
  5.  Serial Number
  6.  Foreign/PCT Application Re:
  7.  Other:

## Correct data

- 1.
- 2.
3. USE OF FXR LIGANDS (see Preliminary Amendment filed August 8, 2003)
- 4.
- 5.
- 6.
- 7.

  
 Virginia J. Bennett

Registration No.: 37,092

Date: July 19, 2004  
 GlaxoSmithKline  
 Five Moore Drive, P.O. Box 13398  
 Research Triangle Park, NC 27709  
 Phone: 919-483-1012  
 Fax: 919-483-7988

## CERTIFICATE OF MAILING (37 CFR 1.8)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being facsimile transmitted or deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: M/S XXX, Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450.

Date: July 19, 2004
  
 MARJORIE J. PFEIFFER

JUL. 19. 2004 4:29PM

GLAXO WELLCOME

NO. 4348 P. 3  
page 1 of 2

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
 United States Patent and Trademark Office  
 Address: COMMISSIONER FOR PATENTS  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

IPM / Val

APPL NO.	FILING OR 371 (C) DATE	ART UNIT	FIL FEE REC'D	ATTY.DOCKET NO		DRAWINGS	TOT CLMS	IND CLMS
10/637,190	08/08/2003	1625	834	PU3616US2		7	6	4

23347

DAVID J LEVY, CORPORATE INTELLECTUAL PROPERTY  
 GLAXOSMITHKLINE  
 FIVE MOORE DR., PO BOX 13398  
 RESEARCH TRIANGLE PARK, NC 27709-3398

NOV 11 2003

CONFIRMATION NO. 5880

## FILING RECEIPT



NO000000011215058\*

Date Mailed: 11/07/2003

GLOBAL INTELLECTUAL PROPERTY

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

## Applicant(s)

Curt Dale Haffner, Durham, NC;  
 Patrick Reed Maloney, Durham, NC;  
 Timothy Mark Willson, Durham, NC;

## Domestic Priority data as claimed by applicant

This application is a CON of 09/868,397 06/18/2001 PAT 6,639,078  
 which is a 371 of PCT/US99/30947 12/22/1999  
 which claims benefit of 60/135,097 12/23/1998

## Foreign Applications

If Required, Foreign Filing License Granted: 11/07/2003

Projected Publication Date: 02/19/2004

Non-Publication Request: No

Early Publication Request: No

Title

Assays for ligands for nuclear receptors

**Preliminary Class**

546

---

**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related application(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).